Q-omics provides the consensus-scored MIR298 profile across patient tissues and cancer cell-line models. MIR298 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, MIR298 is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, MIR298 RNA expression shows 9,783 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KICH, BRCA, and GBM as cancer lineages where MIR298 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR298 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR298 survival associations across molecular data types. MIR298 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR298 RNA expression–survival associations across cancer types. High MIR298 expression shows unfavorable associations in KICH, KIRP, MESO, LUSC, LGG and CHOL. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for MIR298 RNA expression.
This table summarizes MIR298 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR298. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR298 shows lower tumor expression in BRCA, UCEC and LUAD. The BRCA box plot shows higher MIR298 RNA expression in normal versus tumor tissue (log2 FC = −0.319, t-test p < 0.001).
This table shows molecular features associated with MIR298 in patient tissues and cancer cell lines. In patient samples, MIR298 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
